Clinical Trial Update: Liver Test Study of Using JKB-122 in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on JKB-122 for autoimmune hepatitis in patients refractory or intolerant to current therapies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hepatitis

Drugs mentioned

• JKB-122

Snippet

Sponsor: TaiwanJ Pharmaceuticals Co., Ltd | Conditions: Autoimmune Hepatitis | Phase 2 | Status: COMPLETED